Dishman Pharmaceuticals and Chemicals has acquired further 50% stake in Schutz Dishman Biotech, a Joint Venture Indian Company, from the existing JV Partner i.e. Schutz & Co Beteiligungsgesellschaft MBH, Germany for a consideration of EURO 300,000.
The said acquisition will help the company in backward integration for some of its existing products and for manufacturing other APIs. Presently, company is holding 22.33% stake in Schutz Dishman and after acquisition of further 50% stake, Schutz Dishman will become subsidiary of the Company.
Schutz Dishman Biotech (Schutz Dishman) is engaged in the business of manufacturing of Bulk Drugs, Drug formulations and performance Chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of DIshman’s Bavla manufacturing facility.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: